Halozyme Therapeutics Inc

Healthcare · Biotechnology

115.20$ +2.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Halozyme Therapeutics Inc (HALO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 481 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement HALO
Line item	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	216	230	196	231	290	298	265	326	354	452	377	481	1,664
Cost of Revenue	55	52	46	57	49	42	66	64	73	102	109	79	363
Gross Profit	161	178	150	174	241	256	199	262	281	350	268	402	1,301
Research & Development	17	21	19	21	18	20	15	18	17	32	26	28	102
Selling, General & Administrative	35	38	35	36	41	42	42	42	46	77	58	57	238
Total Operating Expenses	73	77	54	57	77	80	57	59	63	95	83	114	356
Operating Income	88	101	96	117	163	176	142	202	218	254	185	288	944
Interest Expense	4.5	5.2	4.5	4.5	4.5	4.5	4.5	4.4	4.3	4.9	5.5	5.6	20
Pre-Tax Income	102	101	96	118	165	178	144	205	219	-101	180	285	583
Income Tax Expense	20	16	19	24	28	41	26	40	44	41	30	55	170
Net Income	82	85	77	93	137	137	118	165	175	-142	150	230	414
EBITDA	129	127	121	143	190	203	169	230	244	-69	220	320	714

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings